</Agent System Instructions>
<Blinded Review: TIME_ANON_0154>
**Composite Score:** 4.9 / 10.0 (Rigor: 1.4/3.5 | Claims: 1.2/2.5 | Biology: 1.2/2.0 | Reproducibility: 1.1/2.0)
**Bias Category:** Technical/Assay
**Verdict:** Major Revision
**Study Modality:** Hybrid Computational + Wet-Lab
**Technology Maturity:** Mature/Classical
**Epistemic Stage:** Translational/Preclinical/Biomarker

---

### 1. Executive Summary
This study evaluates three $\beta$-carboline alkaloids from *Peganum harmala*—harmine, harmaline, and harmalacidine HCl—for *in vitro* anti-influenza A (H1N1) activity (MTT cytotoxicity and plaque reduction in Vero-E6 cells), antibacterial and anti-biofilm activity against 13 clinical *Staphylococcus aureus* (MSSA) isolates (agar well diffusion, broth microdilution MIC, crystal violet biofilm inhibition, $\text{OD}_{260}$ nucleic acid leakage, ONPG $\beta$-galactosidase membrane permeability, SEM, and qRT-PCR of *icaA*, *fnbA*, and *cna*), and *in silico* AutoDock Vina molecular docking against *S. aureus* AgrA (`4G4K`) and H1N1 neuraminidase (`3TI6`) and PB2 (`4CB4`). While the multi-assay phenotypic screening shows consistent membrane-disrupting and anti-biofilm effects against *S. aureus* at $0.25\text{--}0.5\text{ mg/mL}$, the manuscript is undermined by a dangerously narrow antiviral selectivity index ($\text{SI} = 2.08$) confounded by cytotoxicity, unconventional H1N1 assay conditions lacking positive antiviral controls, technical pseudoreplication in the membrane assays, and several editorial/statistical errors.

### 2. Methodological & Statistical Audit
- **Confounded H1N1 Antiviral Activity and Narrow Selectivity Index ($\text{SI} = 2.08$):**
  - For harmalacidine HCl, the authors report $\text{CC}_{50} = 141.7\text{ }\mu\text{g/mL}$ in Vero-E6 cells and $\text{IC}_{50} = 68.2\text{ }\mu\text{g/mL}$ in the H1N1 plaque reduction assay, yielding a selectivity index ($\text{SI} = \text{CC}_{50}/\text{IC}_{50}$) of only **$2.08$** (and harmaline $\text{IC}_{50} = 109.1\text{ }\mu\text{g/mL}$ vs. $\text{CC}_{50} = 439.9\text{ }\mu\text{g/mL}$, $\text{SI} = 4.03$). In antiviral pharmacology, an $\text{SI} \approx 2$ indicates that plaque reduction overlaps substantially with sub-lethal host cell metabolic toxicity (in Figure 2, Vero-E6 cell viability already drops to $\sim 70\%$ at $62.5\text{ }\mu\text{g/mL}$ harmalacidine HCl, the exact concentration claimed to give $55.6\%$ viral inhibition in Table 1).
  - Moreover, the H1N1 plaque assay was performed in **Vero-E6 cells** (African green monkey kidney cells typically used for coronaviruses) rather than standard MDCK cells, without specifying the H1N1 viral strain/accession, whether exogenous TPCK-trypsin was supplied for hemagglutinin cleavage, or including any positive antiviral control drug (e.g., oseltamivir or baloxavir) in the wet-lab assay.
- **Technical Pseudoreplication Treated as Independent Replicates (Figure 3):**
  - The caption to Figure 3 ($\text{OD}_{260}$ nucleic acid release and ONPG $\beta$-galactosidase membrane permeability) explicitly states that error bars represent *"mean ± standard deviation (SD) from n = 3 technical repeats of the same isolate"*, which are then subjected to one-way ANOVA and Tukey's post-hoc tests as if they were independent biological replicates.
- **Statistical & Editorial Errors in Text and Equations:**
  - **Missing Equations (Sections 2.3.1 & 2.3.2, lines 44 and 51):** Both *"Cell viability (%) was determined using the following formula:"* and *"Viral inhibition (%) was calculated using the following equation:"* are followed by blank lines—the equations were omitted from the manuscript.
  - **Inverted P-value Inequality (Section 3.2.5, line 173):** Reporting the Chi-square test for biofilm category shift (Table 3: $6/13$ non/weak before treatment vs. $12/13$ non/weak after harmalacidine HCl treatment, $\chi^2 = 6.19, p = 0.013$), the text writes: *"we have found that the shift from moderate/strong to weak/non-biofilm producers was significant (p > 0.05)"*—writing `p > 0.05` instead of `p < 0.05`.
  - **Gene Symbol Inconsistency:** The collagen adhesin gene is called `cna` in Sections 2.4.6 and 3.2.6, but labeled `can` in Figure 5 and Table 2 (*"fnbA, can, and icaA"*).
- **Superficial Molecular Docking Without Validation:**
  - AutoDock Vina docking scores ($-5.6$ to $-7.3\text{ kcal/mol}$) are moderate and generic for small planar tricyclic alkaloids; no enzymatic inhibition assays (e.g., neuraminidase cleavage assay or PB2 cap-binding assay) were performed to test whether the alkaloids actually interact with NA, PB2, or AgrA.

### 3. Biological / Experimental Grounding & Claim Proportionality
- **[Moderately Supported]** Harmine, harmaline, and harmalacidine HCl inhibit planktonic growth ($\text{MIC} = 0.5\text{ mg/mL}$ for harmine/harmaline; $1.0\text{ mg/mL}$ for harmalacidine HCl), compromise cytoplasmic membrane integrity, and reduce biofilm formation and adhesion gene (*icaA*, *fnbA*, *cna*) expression at sub-MIC concentrations in MSSA isolates.
- **[Overstated]** Calling harmalacidine HCl a "promising dual-action therapeutic agent" with "the strongest antiviral activity" ($\text{IC}_{50} = 68.2\text{ }\mu\text{g/mL}$) ignores the fact that it is also the most cytotoxic compound ($\text{CC}_{50} = 141.7\text{ }\mu\text{g/mL}$, $\text{SI} = 2.08$) and has the *weakest* antibacterial MIC ($1.0\text{ mg/mL}$).
- **[Fragile]** The *in silico* docking claims regarding dual targeting of H1N1 PB2/NA and *S. aureus* AgrA are unvalidated by biochemical target-engagement assays and obtain modest binding energies ($-5.6$ to $-7.3\text{ kcal/mol}$).

### 4. Reproducibility & Data Completeness
- **Missing Strain Provenance & Chemical Purity:** The manuscript does not report the chemical source, synthesis, or purity ($\text{HPLC/NMR}$) of harmine, harmaline, and harmalacidine HCl, nor does it identify the specific H1N1 influenza strain or the clinical provenance/accession numbers of the 13 MSSA isolates.
- **Primer Sequences:** qRT-PCR primer sequences for *icaA*, *fnbA*, *cna*, and *16S rRNA* are provided in Table 2, and PDB accessions (`4G4K`, `3TI6`, `4CB4`) are specified.
</Blinded Review: TIME_ANON_0154>
